Supplemental Material

Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody

Noriko Makita¹, Takao Ando², Junichiro Sato¹, Katsunori Manaka¹, Koji Mitani¹, Yasuko Kikuchi³, Takayoshi Niwa³, Masanori Ootaki⁴, Yuko Takeba⁴, Naoki Matsumoto⁴, Atsushi Kawakami², Toshihisa Ogawa⁵, Masaomi Nangaku¹, and Taroh Iiri¹,⁴

¹Department of Endocrinology and Nephrology, The University of Tokyo School of Medicine, Tokyo, 113-8655 Japan. ²Division of Endocrinology and Metabolism, Nagasaki Graduate School of Biomedical Sciences, Nagasaki, 852-8501 Japan. ³Department of Breast and Endocrine Surgery, The University of Tokyo School of Medicine, Tokyo, 113-8655 Japan. ⁴Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, 216-8511 Japan. ⁵Breast Center, Dokkyo Medical University Koshigaya Hospital, Saitama, 343-8555, Japan.

Supplemental Figure Legends

Supplemental Figure S1. Temporal profile of serum Ca levels in our AHH patient. The corrected calcium levels in our patient’s serum over time are shown. Shortly after the episode of spontaneous exacerbation of hypercalcemia, treatment with cinacalcet was started (as also described in Figure 1A).

Supplemental Figure S2. Effects of commercial anti CaSR (214-235) antibody on CaSR-dependent signals. Effects of commercial anti CaSR (214-235) antibody on CaSR-dependent IP1 accumulation using IP-One ELISA kit (CIS BioInternational) (left: Ca 1.0 mM) and ERK1/2 phosphorylation (right: Ca 2.5 mM) in HEK293 cells stably expressing CaSR. Statistical analysis was performed using Dunnett’s test (left) and Student’s t test (right). Values represent means ±
SEM of triplicate determinations. Each set of results is representative of at least two additional experiments. *$P < 0.05$; **$P < 0.01$; ***$P < 0.0001$
Supplemental Figure S1. Temporal profile of serum Ca levels in our AHH patient. The corrected calcium levels in our patient’s serum over time are shown. Shortly after the episode of spontaneous exacerbation of hypercalcemia, treatment with cinacalcet was started (as also described in Figure 1A).
Supplemental Figure S2. Effects of commercial anti CaSR (214-235) antibody on CaSR-dependent signals. Effects of commercial anti CaSR (214-235) antibody on CaSR-dependent IP1 accumulation using IP-One ELISA kit (CIS BioInternational) (left: Ca 1.0 mM) and ERK1/2 phosphorylation (right: Ca 2.5 mM) in HEK293 cells stably expressing CaSR. Statistical analysis was performed using Dunnett’s test (left) and Student’s t test (right). Values represent means ± SEM of triplicate determinations. Each set of results is representative of at least two additional experiments. *P < 0.05; **P < 0.01; ***P < 0.0001.